Literature DB >> 15232344

Melatonin treatment of day-night rhythm disturbances and sundowning in Alzheimer disease: an open-label pilot study using actigraphy.

Richard Mahlberg, Dieter Kunz, Igor Sutej, Klaus-Peter Kühl, Rainer Hellweg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15232344     DOI： 10.1097/01.jcp.0000132443.12607.fd

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  28 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Chronic treatment with a selective inhibitor of casein kinase I delta/epsilon yields cumulative phase delays in circadian rhythms.

Authors:  Jeffrey Sprouse; Linda Reynolds; Robin Kleiman; Barbara Tate; Terri A Swanson; Gary E Pickard
Journal:  Psychopharmacology (Berl)       Date:  2010-04-21       Impact factor: 4.530

3.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

Review 4.  Alternatives to atypical antipsychotics for the management of dementia-related agitation.

Authors:  Michael J Passmore; David M Gardner; Yvette Polak; Kiran Rabheru
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

5.  Altered temporal patterns of anxiety in aged and amyloid precursor protein (APP) transgenic mice.

Authors:  Tracy A Bedrosian; Kamillya L Herring; Zachary M Weil; Randy J Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-27       Impact factor: 11.205

Review 6.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

7.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

8.  Therapeutic application of melatonin in mild cognitive impairment.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Analía M Furio; Luis I Brusco
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

9.  Medical hypothesis: Light at night is a factor worth considering in critical care units.

Authors:  Randy J Nelson; A Courtney DeVries
Journal:  Adv Integr Med       Date:  2017-12-21

Review 10.  Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.

Authors:  Masaomi Miyamoto
Journal:  CNS Neurosci Ther       Date:  2009       Impact factor: 5.243
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.